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X-RAY STRUCTURES OF PfDxr IN COMPLEX WITH 6c,d
I. Synthesis of β-aryl analogues
Blocking the MEP pathway for isoprenoid biosynthesis offers interesting prospects for inhibiting Plasmodia growth. Fosmidomycin (1) and its homologue FR900098 (2) potently inhibit 1-deoxy-D-xylulose-5-
phosphate reductoisomerase (Dxr), a key enzyme in this pathway. Although fosmidomycin is a remarkably safe antimalarial agent, low oral absorption, short serum half-life and malaria recrudescence
preclude its use in monotherapy. The development of more lipophilic Dxr inhibitors able to passively permeate into cells with improved pharmacokinetic properties could lead to more efficacious agents.
Previously, we discovered that analogue 4, featuring a 3,4-dichlorophenyl substituent in -position of the phosphonate, surpasses fosmidomycin’s potency in inhibiting P. falciparum growth. Here we explored
the introduction of aryl or aralkyl substituents at the β-position of the known hydroxamate analogue 3.
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We studied the effect of introducing substituents in β-position of the hydroxamate analogue 3. While direct addition of a β-aryl moiety resulted in poor P. falciparum Dxr inhibition, longer linkers between the carbon
backbone and the phenyl ring were generally associated with better binding to the enzyme. X-ray structures of the parasite Dxr-inhibitor complexes show that the “longer” compounds generate a substantially
different flap structure, in which a key tryptophan residue is displaced, and the aromatic group of the ligand lies between the tryptophan and the hydroxamate’s methyl group. Several analogues emerged as highly
potent inhibitors of Plasmodium falciparum in vitro growth. In some cases (e.g. for compounds 7b and 7f) good Dxr inhibitory activity failed to translate in good in vitro activity against the parasite, which may be
due to inefficient uptake. Compounds 5a-e likewise failed to inhibit EcDxr and MtbDxr while 6c was optimal for inhibition of these enzymes.
Figure 1: Inhibition of isoprenoid
biosynthesis via the MEP pathway by
fosmidomycin and compound 2.
Reagents and conditions: i) Boc2O, DMAP, tert-BuOH, rt, overnight; ii) (BnO)2OPMe (for 10a-c, f),
(EtO)2OPMe (for 12d & 12e), n-BuLi, THF, -78 °C, 2.5 h; iii) (a) TFA, CH2Cl2, 45 min, 0 °C to rt; (b)
MeNH(OBn), EDC, DMAP, CH2Cl2, rt, overnight; iv) H2, Pd/C, MeOH, NaOHaq., 25 °C, 10–15 min; v)
BCl3, CH2Cl2, -78 °C, 1 h; vi) (a) TMSBr, BSTFA, CH2Cl2, 0 °C to rt, 22 h; (b) H2O, NH4OHaq.
Reagents and conditions: i) Dess-Martin periodinane, CH2Cl2; ii) Ph3P=CHCOOtert-Bu, toluene,
120 °C; iii) (BnO)2OPMe, n-BuLi, THF, -78 °C, 2.5 h; iv) (a) TFA, CH2Cl2, 45 min, 0 °C to rt; (b)
MeNH(OBn), EDC, DMAP, CH2Cl2, rt; v) H2, Pd/C, MeOH, NaOHaq., 25 °C, 10–15 min.
SYNTHESIS
II. Synthesis of β-phenylalkyl homologues
III. Synthesis of β-arylpropyl homologues
Reagents and conditions: i) but-3-yn-1-ol, PdCl2(PPh3), CuI, Et3N, 117 °C; ii) H2, Pd/C, MeOH; iii) Dess-
Martin periodinane, CH2Cl2; iv) Ph3P=CHCOOtert-Bu, toluene, 120 °C; v) (BnO)2OPMe, n-BuLi, THF, -
78 °C; vi) (a) TFA, CH2Cl2, 45 min, 0 °C to rt; (b) MeN(OBn)H, EDC, DMAP, CH2Cl2, 18 h rt; vii) H2,
Pd/C, MeOH, NaOHaq., 25 °C, 10-15 min.
BIOLOGICAL RESULTS
INTRODUCTION & GOAL
Table 1. IC50 ± sd values for recombinant Dxr from P. falciparum and
MIC50 values against in vitro growth of P. falciparum K1 strain.
Cmpd 
PfDxr 
IC50 (µM) 
P. falciparum-K1 
MIC50 (µM) 
Cmpd 
PfDxr 
IC50 (µM) 
P. falciparum-K1 
MIC50 (µM) 
Fos (1) 0.036 ± 0.006 1.73 ± 0.89 6c 0.117 ± 0.012 0.43 ± 0.09 
FR (2) 0.018 0.42 ± 0.17 6d 0.069 ± 0.005 < 0.25±0.00 
3  0.26 ± 0.02 7a 0.56 ± 0.007 2.71 
5a  3.3 ± 0.17 >64 7b 0.05 ± 0.007 14.11 
5b 9.3 ± 0.75 >64 7c 0.12 ± 0.006 6.59 
5c 18.8 ± 4.2 >64 7d 0.15 ± 0.006 10.44 
5d  >64 7e  3.2 ± 0.115 > 64.00 
5e  >64 7f  0.07 ± 0.001 10.77 
5f  0.74 ± 0.13 7g 0.27 ± 0.01 > 64.00 
6a  ≥56.8 ± 10.1 7h 1.6 ± 0.25 > 64,00 
6b 1.36 ± 0.02 35.4 ± 8.7 7i  0.28 ± 0.002 56.01 
   7j 0.87 ± 0.03 41.24 
 
Figure 2. The active site of PfDxr bound to 6c and 6d. Water molecules are shown as small red spheres,
and the Mn2+ ion is gold.
(A) Electron density for the inhibitor 6c and selected nearby residues. (B) Hydrogen-bond interactions
(magenta) between 6c and protein or solvent and metal coordination (gold); blue and cyan bubbles indicate
close contacts (< 3.7 Å) between the phenyl group of 6c and the indole ring of Trp296 from the flap, or
within the inhibitor, respectively. (C) The structures of bound 6c and 6d are superimposed. The flap in the
complex with 5a is shown in magenta for comparison.
CONCLUSIONS
